Admetsys, a startup developing artificial pancreas tech for hospitals and surgical care, won an investment from T1D Exchange. The terms of the financing were not disclosed. A collaboration between the 2 groups is part of T1D Exchange’s initiative to support the development of automated insulin delivery technology, according to the organization. Hospitalizations can be challenging for […]
Featured
Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial
Living Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety. The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with […]
Inhaled Parkinson’s treatment improves motor function in Phase III
Shares in Acorda Therapeutics (NSDQ:ACOR) jumped this morning after the company reported that its inhaled Parkinson’s drug significantly improved motor function in a Phase III trial. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Phase III Span-Pd trial enrolled 339 patients with […]
BD wins 510(k) for intestinal bacteria diagnostic
Becton Dickinson (NYSE:BDX) said today that it won 510(k) clearance from the FDA for its molecular test that detects harmful intestinal bacteria causing infectious diarrhea. With the approval of its BD Max extended enteric bacteria panel, the company said the majority of pathogens causing acute gastroenteritis can be detected on its automated BD Max molecular […]
Hydrogel tech boosts success of transplanted insulin-producing cells
A hydrogel material embedded with a protein to improve blood vessel growth may boost the success rate of transplanting insulin-producing islet cells into patients with Type I diabetes, according to a preclinical study published in the journal Science Advances. In the newly-published work, supported by the National Institutes of Health and the Juvenile Diabetes Research Foundation, […]
Report finds Pfizer has hiked prices of nearly 100 drugs this year
As other major pharma players like Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) vow to limit annual price hikes, a report by the Financial Times found that Pfizer (NYSE:PFE) has raised prices on 91 drugs by an average of 21% in 2017. The most recent price hike at the start of June was the company’s 2nd for […]
Insulet brings on new chief commercial exec | Personnel Moves – June 5, 2017
Insulet (NSDQ:PODD) last month named Bret Christensen as its chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy. He most recently served as GM of Myriad Genetics’ preventive care business division. He has also worked as VP of sales and marketing of the gynecologic surgical products unit at Hologic. “I […]
Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial
Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial. The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib. Data from the 360-patient trial […]
AntriaBio seeks FDA nod for trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes. The first-in-human study is slated to evaluate the […]
Novartis, IBM Watson collab to optimize care for patients with advanced breast cancer
Novartis (NYSE:NVS) said today that it inked a deal with IBM Watson Health to optimize care and improve outcomes for patients with advanced breast cancer. The 2 companies plan to develop a “cognitive solution” using real-world patient data and analytics to better understand expected outcomes of breast cancer treatment options and develop personalized treatment plans […]